<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> have been suggested as markers for a high risk of recurrent cardiovascular events in young survivors of an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are few data to confirm or refute this hypothesis </plain></SENT>
<SENT sid="2" pm="."><plain>In a cohort study, we have measured anticephalin (aCEPHA) and anticardiolipin (aCL) antibodies in a group of patients surviving an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Of 597 patients studied, 13.2% were IgG or IgM aCEPHA positive compared with 4.4% of a reference population (n = 158; p = 0.002) </plain></SENT>
<SENT sid="4" pm="."><plain>In a multivariate analysis, adjusted for major <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, neither aCEPHA (IgG or IgM) nor a CL (IgG or IgM) was an independent risk factor for mortality, reinfarction, or non-haemorrhagic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Although an increased proportion of survivors of a <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> have <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, the presence of such antibodies is not a risk factor for subsequent coronary or cerebrovascular <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>